PE20171620A1 - Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas - Google Patents

Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas

Info

Publication number
PE20171620A1
PE20171620A1 PE2017002102A PE2017002102A PE20171620A1 PE 20171620 A1 PE20171620 A1 PE 20171620A1 PE 2017002102 A PE2017002102 A PE 2017002102A PE 2017002102 A PE2017002102 A PE 2017002102A PE 20171620 A1 PE20171620 A1 PE 20171620A1
Authority
PE
Peru
Prior art keywords
sulfonimidoylpurinone
prophylaxis
treatment
viric
infections
Prior art date
Application number
PE2017002102A
Other languages
English (en)
Inventor
Chungen Liang
Kun Miao
Jianping Wang
Hongying Yun
Xiufang Zheng
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20171620A1 publication Critical patent/PE20171620A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Referida a un compuesto de formula I, donde: R1 es alquilo C1-C6, haloalquilo C1-C6, entre otros; R2 es alquilo C1-C6, fenil alquilo C1-C6, entre otros y R3 es H. Son compuestos preferidos: 6-amino-9-[(4-clorofenil)metil]-2(propilsulfonimidoil)-7H-purin-8-ona; 6-amino-9-bencil-2-(etilsulfonimidoil)-7H-purin-8-ona; entre otros. Tambien se refiere a un procedimiento de obtencion y a una composicion farmaceutica. Dichos compuestos derivados de sulfonimidoilpurinona son agonistas de los receptores de tipo Toll (TLR), siendo utiles en el tratamiento o profilaxis de la infeccion por el virus de la hepatitis B (VHB)
PE2017002102A 2015-05-08 2016-05-04 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas PE20171620A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2015078507 2015-05-08
CN2016078785 2016-04-08

Publications (1)

Publication Number Publication Date
PE20171620A1 true PE20171620A1 (es) 2017-11-02

Family

ID=55910966

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002102A PE20171620A1 (es) 2015-05-08 2016-05-04 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas

Country Status (33)

Country Link
US (3) US9708325B2 (es)
EP (1) EP3294740B1 (es)
JP (1) JP6738352B2 (es)
KR (1) KR102690131B1 (es)
CN (1) CN107580596B (es)
AR (1) AR104528A1 (es)
AU (3) AU2016260683B2 (es)
BR (1) BR112017023959B1 (es)
CA (1) CA2982704C (es)
CL (1) CL2017002745A1 (es)
CO (1) CO2017009994A2 (es)
CR (1) CR20170496A (es)
DK (1) DK3294740T3 (es)
ES (1) ES2753777T3 (es)
HK (1) HK1247925A1 (es)
HR (1) HRP20191942T1 (es)
HU (1) HUE045906T2 (es)
IL (2) IL254947B (es)
LT (1) LT3294740T (es)
MX (2) MX2017014033A (es)
MY (1) MY182353A (es)
NZ (1) NZ735648A (es)
PE (1) PE20171620A1 (es)
PH (1) PH12017502009A1 (es)
PL (1) PL3294740T3 (es)
PT (1) PT3294740T (es)
RS (1) RS59435B1 (es)
RU (1) RU2745269C2 (es)
SG (1) SG10202108841YA (es)
SI (1) SI3294740T1 (es)
TW (2) TWI706954B (es)
UA (1) UA120450C2 (es)
WO (1) WO2016180695A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA120450C2 (uk) 2015-05-08 2019-12-10 Ф. Хоффманн-Ля Рош Аг Сполуки і похідні сульфонімідоїлпуринону для лікування і профілактики вірусної інфекції
SI3504210T1 (sl) * 2016-08-29 2021-08-31 F. Hoffmann-La Roche Ag 7-substituirane sulfonimidoilpurinonske spojine za zdravljenje virusne okužbe in zaščito pred njo
EP3970750A1 (en) * 2016-09-13 2022-03-23 F. Hoffmann-La Roche AG Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
EP3752505B1 (en) 2018-02-12 2023-01-11 F. Hoffmann-La Roche AG Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
RU2020131012A (ru) * 2018-02-28 2022-03-28 Ф. Хоффманн-Ля Рош Аг 7-замещенные соединения сульфонимидоилпуринонов и их производные для лечения и профилактики рака печени
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
MX2021009644A (es) * 2019-02-12 2021-09-08 Ambrx Inc Composiciones que contienen, metodos y usos de conjugados de anticuerpo-agonista de tlr.
EP4031544B1 (en) 2019-09-20 2024-02-28 Syngenta Crop Protection AG Pesticidally active heterocyclic derivatives with sulfur and sulfoximine containing substituents
WO2024013205A1 (en) 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Phosphorylpurinone compounds for the treatment of cancer
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
AU2006242920A1 (en) * 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
EA021377B9 (ru) * 2008-12-09 2015-09-30 Джилид Сайэнс, Инк. Модуляторы толл-подобных рецепторов
US20110150836A1 (en) 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
IN2014MN00862A (es) 2011-11-09 2015-04-17 Janssen R & D Ireland
AU2014242954B2 (en) 2013-03-29 2018-03-15 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
EA032824B1 (ru) 2014-08-15 2019-07-31 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
UA120450C2 (uk) * 2015-05-08 2019-12-10 Ф. Хоффманн-Ля Рош Аг Сполуки і похідні сульфонімідоїлпуринону для лікування і профілактики вірусної інфекції
SI3504210T1 (sl) * 2016-08-29 2021-08-31 F. Hoffmann-La Roche Ag 7-substituirane sulfonimidoilpurinonske spojine za zdravljenje virusne okužbe in zaščito pred njo

Also Published As

Publication number Publication date
US9708325B2 (en) 2017-07-18
AU2016260683B2 (en) 2020-10-29
CL2017002745A1 (es) 2018-05-18
US20200109144A1 (en) 2020-04-09
MY182353A (en) 2021-01-20
HK1247925A1 (zh) 2018-10-05
AU2016260683A1 (en) 2017-10-12
CA2982704A1 (en) 2016-11-17
HRP20191942T1 (hr) 2020-01-10
RU2017142577A (ru) 2019-06-10
IL254947B (en) 2021-02-28
ES2753777T3 (es) 2020-04-14
PT3294740T (pt) 2019-10-29
CR20170496A (es) 2017-12-05
NZ735648A (en) 2023-06-30
CO2017009994A2 (es) 2018-02-20
IL280769A (en) 2021-04-29
JP2018515509A (ja) 2018-06-14
IL280769B2 (en) 2023-07-01
JP6738352B2 (ja) 2020-08-12
CA2982704C (en) 2023-10-24
LT3294740T (lt) 2019-11-25
SI3294740T1 (sl) 2019-12-31
AU2020256348A1 (en) 2020-11-12
AU2022204666A1 (en) 2022-07-21
US10399983B2 (en) 2019-09-03
BR112017023959A2 (pt) 2018-07-17
HUE045906T2 (hu) 2020-01-28
BR112017023959B1 (pt) 2023-05-02
DK3294740T3 (da) 2019-11-04
WO2016180695A1 (en) 2016-11-17
EP3294740B1 (en) 2019-09-04
RS59435B1 (sr) 2019-11-29
AR104528A1 (es) 2017-07-26
PH12017502009A1 (en) 2018-03-26
TW201716410A (zh) 2017-05-16
RU2017142577A3 (es) 2019-10-31
MX2020010949A (es) 2022-06-16
PL3294740T3 (pl) 2020-03-31
US11242345B2 (en) 2022-02-08
US20160326177A1 (en) 2016-11-10
UA120450C2 (uk) 2019-12-10
KR102690131B1 (ko) 2024-07-31
IL254947A0 (en) 2017-12-31
RU2745269C2 (ru) 2021-03-22
TW202108584A (zh) 2021-03-01
US20170275286A1 (en) 2017-09-28
TWI706954B (zh) 2020-10-11
MX2017014033A (es) 2018-03-01
CN107580596A (zh) 2018-01-12
KR20180003612A (ko) 2018-01-09
EP3294740A1 (en) 2018-03-21
AU2020256348B2 (en) 2022-06-16
SG10202108841YA (en) 2021-09-29
IL280769B1 (en) 2023-03-01
TWI768467B (zh) 2022-06-21
CN107580596B (zh) 2020-07-14

Similar Documents

Publication Publication Date Title
PE20171620A1 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas
CL2019000271A1 (es) Inhibidores de polimerasa hcv. (divisional solicitud 201600493)
PE20160686A1 (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b
PE20171648A1 (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la capsida del vhb
CL2018003492A1 (es) Hepatitis b agentes antivirales.
AR085327A1 (es) Inhibidores del virus de la hepatitis c
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
PE20142148A1 (es) Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio
CO2021008055A2 (es) Heterociclos funcionalizados como agentes antivirales
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
BR112015021027A2 (pt) compostos terapêuticos
PE20160608A1 (es) Compuestos de quinolina selectivamente sustituida
PE20170679A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales
PE20140522A1 (es) Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
PE20141558A1 (es) Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih
CO6561783A2 (es) Inhibidores del virus flaviviridae
PE20151951A1 (es) Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
CL2020000487A1 (es) Agentes antivirales contra la hepatitis b.
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
AR094966A1 (es) Composiciones farmacéuticas para el tratamiento de infecciones hcv
EA201591220A1 (ru) Новые противовирусные агенты против инфекции вирусом гепатита в
AR093659A1 (es) Derivados ciclicos de nucleosidos y usos de los mismos
PE20110409A1 (es) Compuestos heterociclicos antiviricos
PE20131165A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
PE20141041A1 (es) Compuestos, metodos y formulaciones parasiticidas